These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17938973)

  • 1. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.
    Afzal K; Bagga A; Menon S; Hari P; Jordan SC
    Pediatr Nephrol; 2007 Dec; 22(12):2059-65. PubMed ID: 17938973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
    Bagga A; Hari P; Moudgil A; Jordan SC
    Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center.
    Fujinaga S; Ohtomo Y; Hirano D; Nishizaki N; Someya T; Ohtsuka Y; Kaneko K; Shimizu T
    Clin Nephrol; 2009 Oct; 72(4):268-73. PubMed ID: 19825332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
    Gellermann J; Ehrich JH; Querfeld U
    Nephrol Dial Transplant; 2012 May; 27(5):1970-8. PubMed ID: 21976740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
    Wang J; Mao J; Chen J; Fu H; Shen H; Zhu X; Liu A; Shu Q; Du L
    Nephrology (Carlton); 2016 Jan; 21(1):21-7. PubMed ID: 26697959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
    Sinha A; Gupta A; Kalaivani M; Hari P; Dinda AK; Bagga A
    Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
    Basu B; Babu BG; Mahapatra TK
    Clin Exp Nephrol; 2017 Feb; 21(1):143-151. PubMed ID: 27108294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
    Mendizábal S; Zamora I; Berbel O; Sanahuja MJ; Fuentes J; Simon J
    Pediatr Nephrol; 2005 Jul; 20(7):914-9. PubMed ID: 15891923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
    Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
    Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
    Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
    Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of mycophenolate mofetil versus levamisole therapy in frequently relapsing and steroid dependent childhood nephrotic syndrome - A retrospective comparative analysis.
    Sharma S; Kalra S; Shukla S; Sharma P
    Nephrology (Carlton); 2022 Sep; 27(9):758-762. PubMed ID: 35619554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.
    Moudgil A; Bagga A; Jordan SC
    Pediatr Nephrol; 2005 Oct; 20(10):1376-81. PubMed ID: 15977023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study.
    Senthil Nayagam L; Ganguli A; Rathi M; Kohli HS; Gupta KL; Joshi K; Sakhuja V; Jha V
    Nephrol Dial Transplant; 2008 Jun; 23(6):1926-30. PubMed ID: 17989103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.
    Fujinaga S; Ohtomo Y; Umino D; Takemoto M; Shimizu T; Yamashiro Y; Kaneko K
    Pediatr Nephrol; 2007 Jan; 22(1):71-6. PubMed ID: 17086405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome.
    Day CJ; Cockwell P; Lipkin GW; Savage CO; Howie AJ; Adu D
    Nephrol Dial Transplant; 2002 Nov; 17(11):2011-3. PubMed ID: 12401863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
    Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.
    Baudouin V; Alberti C; Lapeyraque AL; Bensman A; André JL; Broux F; Cailliez M; Decramer S; Niaudet P; Deschênes G; Jacqz-Aigrain E; Loirat C
    Pediatr Nephrol; 2012 Mar; 27(3):389-96. PubMed ID: 21947272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children].
    Ogarek I; Szczęsny-Choruz E; Wierzchowska-Słowiaczek E; Kwinta-Rybicka J; Stec Z; Moczulska A; Wilkosz K; Drożdż D
    Pol Merkur Lekarski; 2018 Apr; 44(262):192-195. PubMed ID: 29775447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for sustained remission in nephrotic syndrome.
    Querfeld U; Weber LT
    Pediatr Nephrol; 2018 Dec; 33(12):2253-2265. PubMed ID: 29750317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.